Dementia
📧 Sign up to get email alerts when something new happens for Dementia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-20EMA Authorised: Rivastigmine Hexal (rivastigmine) — Hexal AG
Rivastigmine Hexal has been authorised for dementia-related indications in the European market.
-
EMA approval · 2026-08-20EMA Authorised: Rivastigmine Sandoz (rivastigmine) — Sandoz GmbH
EMA authorised rivastigmine Sandoz for dementia indications, including Alzheimer disease and Parkinson disease.
-
EMA approval · 2026-08-20EMA Authorised: Rivastigmine 1 A Pharma (rivastigmine) — 1 A Pharma GmbH
EMA authorises rivastigmine 1 A Pharma for Alzheimer's disease, dementia, and Parkinson's disease.
-
EMA approval · 2026-04-24EMA Authorised: Striascan (ioflupane (123l)) — CIS bio international
The EMA authorised Striascan (ioflupane (123I)) from CIS bio international for radionuclide imaging in dementia and movement disorders, with…
-
EMA approval · 2026-02-24EMA Authorised: Exelon (rivastigmine) — Novartis Europharm Limited
The European Medicines Agency authorised Exelon (rivastigmine) for dementia including Alzheimer's disease and Parkinson's disease, with Nova…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-01-16EMA Authorised: Tauvid (Flortaucipir (18F)) — Eli Lilly Nederland B.V.
The EMA authorized Tauvid, a radiopharmaceutical PET imaging agent (flortaucipir F18) developed by Eli Lilly Nederland B.V. The product is i…
-
EMA approval · 2026-01-16EMA Authorised: Amyvid (florbetapir (18F)) — Eli Lilly Nederland B.V.
The European Medicines Agency authorised Amyvid (florbetapir (18F)) for radionuclide imaging. The marketing authorization holder is Eli Lill…
-
EMA approval · 2026-01-16EMA Authorised: Rivastigmine Hexal (rivastigmine) — Hexal AG
Hexal AG's rivastigmine product has been authorized in the EU for dementia-related indications including Alzheimer's disease and Parkinson's…
-
EMA approval · 2026-01-16EMA Authorised: Rivastigmine Sandoz (rivastigmine) — Sandoz GmbH
The European Medicines Agency authorised Rivastigmine Sandoz (rivastigmine) for dementia indications, including Alzheimer's disease and Park…
-
EMA approval · 2026-01-16EMA Authorised: Rivastigmine 1 A Pharma (rivastigmine) — 1 A Pharma GmbH
The EMA authorised rivastigmine from 1 A Pharma GmbH for use in Alzheimer's disease, dementia, and Parkinson's disease.
-
EMA approval · 2025-07-17EMA Authorised: Nimvastid (rivastigmine) — Krka, d.d., Novo mesto
EMA authorised Nimvastid (rivastigmine) by Krka for treatment of dementia, including Alzheimer's disease and Parkinson's disease.
-
FDA approval · 2025-06-23FDA Approved: VIZAMYL — Supplemental Application (GE Healthcare Inc. (Medi-Physics, Inc. dba GE Healthcare))
FDA approved a supplemental application for VIZAMYL (flutemetamol F-18) from GE Healthcare.
-
EMA approval · 2025-06-13EMA Authorised: Rivastigmine Actavis (rivastigmine hydrogen tartrate) — Actavis Group PTC ehf
EMA authorised Rivastigmine Actavis (rivastigmine hydrogen tartrate) for dementia-related indications including Alzheimer's disease and Park…
-
FDA approval · 2025-06-10FDA Approved: VIZAMYL — Supplemental Application (GE Healthcare Inc. (Medi-Physics, Inc. dba GE Healthcare))
FDA approved a supplemental application for Vizamyl (flutemetamol F-18) by GE Healthcare, authorizing changes to the product’s labeling.
-
EMA approval · 2025-04-15EMA Authorised: Prometax (rivastigmine) — Almirall, S.A.
The EMA authorised Prometax (rivastigmine) for the treatment of Alzheimer's disease, Parkinson's disease, and dementia. The decision date is…
-
EMA approval · 2024-11-15EMA Authorised: Celsunax (ioflupane (123i)) — Pinax Pharma GmbH
EMA authorised Celsunax (ioflupane (123I)) by Pinax Pharma GmbH for radionuclide imaging to aid the assessment of movement disorders and dem…
-
FDA approval · 2022-06-08FDA Approved: NEURACEQ — Supplemental Application (Lantheus Biosciences Ltd.)
The FDA granted a supplemental approval for NEURACEQ (florbetaben F-18), a PET imaging agent. The approval expands its use for evaluating be…
-
FDA approval · 2020-01-10FDA Approved: VIZAMYL — Supplemental Application (GE Healthcare Inc. (Medi-Physics, Inc. dba GE Healthcare))
FDA approved a supplemental application for Vizamyl (flutemetamol F-18) from GE Healthcare, expanding its regulatory authorization to includ…
-
FDA approval · 2020-01-10FDA Approved: NEURACEQ — Supplemental Application (Lantheus Biosciences Ltd.)
FDA approved a supplemental application for NEURACEQ (florbetaben F-18) from Lantheus Biosciences Ltd., granting continued approval for its …
-
FDA approval · 2018-07-10FDA Approved: NEURACEQ — Supplemental Application (Lantheus Biosciences Ltd.)
FDA approved a supplemental application for NEURACEQ (Florbetaben F-18) from Lantheus Biosciences Ltd.
-
FDA approval · 2017-06-16FDA Approved: NEURACEQ — Supplemental Application (Lantheus Biosciences Ltd.)
FDA approved a supplemental application for NEURACEQ (Florbetaben F-18) submitted by Lantheus Biosciences Ltd. The action expands the regula…
-
FDA approval · 2016-02-26FDA Approved: FLUDEOXYGLUCOSE F 18 — Supplemental Application (Massachusetts General Hospital)
FDA approved a supplemental application for Fludeoxyglucose F-18 submitted by Massachusetts General Hospital to support its use as a radioph…
-
FDA approval · 2015-05-18FDA Approved: NEURACEQ — Supplemental Application (Lantheus Biosciences Ltd.)
The FDA approved a supplemental application for NEURACEQ (FLORBETABEN F 18) submitted by Lantheus Biosciences Ltd.
-
FDA approval · 2015-05-01FDA Approved: FLUDEOXYGLUCOSE F 18 — Original Application (Biomedical Research Foundation of Northwest Louisiana)
FDA approved Fluorodeoxyglucose F-18 as a diagnostic radiopharmaceutical for positron emission tomography (PET) imaging under an original ap…
-
FDA approval · 2015-02-03FDA Approved: VIZAMYL — Supplemental Application (GE Healthcare Inc. (Medi-Physics, Inc. dba GE Healthcare))
FDA approved a supplemental application for Vizamyl (flutemetamol F-18) from GE Healthcare, indicating regulatory approval of a supplemental…